Sarepta Therapeutics, Inc. (SRPT) Stock
Key stats
- Market cap
- $1.79B
- Price / Earnings ratio
- 119.3x
- EPS (TTM)
- $0.07
- Volume
- Loading
- 52-week high
- $24.68
- 52-week low
- $14.68
Source: third-party data provider, as of November 13, 2026
Compare with SRPT
Recent news

Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?
Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?
SRPT

Sarepta Therapeutics to Present at Upcoming Investor Conferences
Sarepta Therapeutics to Present at Upcoming Investor Conferences
SRPT

Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
SRPT

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
SRPT
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 40.30
- MACD 12/26/9
- -0.35
- EMA 9 of MACD
- -0.17
- MACD histogram
- -0.18
- SMA 50
- $18.87
- Price below SMA 50
- EMA 50
- $18.30
- Price below EMA 50
- SMA 200
- $18.57
- Price below SMA 200
- EMA 200
- $18.95
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Sell
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $1.13 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?
Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?
SRPT

Sarepta Therapeutics to Present at Upcoming Investor Conferences
Sarepta Therapeutics to Present at Upcoming Investor Conferences
SRPT

Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
SRPT

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
SRPT

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
SRPT

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SRPT

Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
SRPT

Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
SRPT

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting
SRPT

Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near
Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near
SRPT
News tone: automated (AI) classification of the article's content, not a price prediction.
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Michael E. Severino M.D. | CEO & Director | 1966 |
| Mr. Ian Michael Estepan | President & COO | 1976 |
| Mr. Ryan H. Wong | Executive VP & CFO | 1979 |
| Ms. Cristin L. Rothfuss J.D. | Executive VP, General Counsel & Company Secretary | 1968 |
| Mr. Douglas S. Ingram Esq., J.D. | Advisor | 1963 |
| Dr. Louise R. Rodino-Klapac Ph.D. | President of Research & Development and Technical Operations | 1978 |
| Rachael Potter Ph.D. | Chief Scientific Officer | — |
| Tamara Thornton | Director of Finance, Treasury & Investor Relations | — |
| Ms. Alison Nasisi | Executive VP & Chief People Officer | — |
| Dr. Diane L. Berry Ph.D. | Executive VP and Chief of Global Policy & Advocacy Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 40.30
- MACD 12/26/9
- -0.35
- EMA 9 of MACD
- -0.17
- MACD histogram
- -0.18
- SMA 50
- $18.87
- Price below SMA 50
- EMA 50
- $18.30
- Price below EMA 50
- SMA 200
- $18.57
- Price below SMA 200
- EMA 200
- $18.95
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $5.00
- Average
- $14.33
- High
- $20.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -3.7 | +9.6 | ||||||||||
| 2022 | -20.8 | +3.2 | +2.8 | -12.4 | -1.3 | +3.3 | +22.8 | +19.5 | +0.4 | +3.7 | +7.7 | +5.4 |
| 2023 | +0.1 | -0.2 | -5.4 | -10.7 | -1.2 | -7.9 | -4.5 | +12.5 | -1.1 | -43.2 | +6.2 | +14.2 |
| 2024 | +23.7 | +4.1 | +0.6 | -1.4 | -0.8 | +27.2 | -9.3 | -5.7 | -7.6 | +3.0 | +8.2 | -5.0 |
| 2025 | -8.4 | -6.2 | -36.9 | +0.8 | -40.1 | -54.7 | -7.3 | +14.4 | +6.1 | +24.3 | -12.7 | +9.1 |
| 2026 | -4.6 | -19.1 | +33.3 | -5.6 | -16.8 | +2.0 | -18.4 | +32.4 | -14.6 | +6.0 | -9.0 |



